Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: A free-standing polymer electrolyte for an electrochromic device includes a polymer network, a plasticizer and an electrolyte salt containing at least one of lithium or sodium ions. The free-standing polymer electrolyte may exclude tetraglyme.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: Aqueous dispersions of chemically and physically stable particles for use in delivery of active pharmaceutical ingredients and processes for their production and use to enhance a biological response to an active pharmaceutical ingredient and prophylactically or therapeutically treat a subject are provided. Vaccines, wherein the active pharmaceutical ingredient is a solution of subunit vaccine antigen mixed with a colloidal dispersion of electrically charged particles and use of such vaccines in immunization are also provided.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatings to increase the temperature of the skin, mucous membranes, eye or eyelids will help treat many conditions including blepharitis and non-healing ulcers. Methods to decrease evaporation, improve wettability and stabilize the tear film, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to improve contact lens tolerability, are provided.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change the ocular surface temperature and other characteristics of biological or contact lens surfaces. Methods for use of these formulations and coatings to increase the temperature of the skin, mucous membranes, eye or eyelids will help treat many conditions including blepharitis and non-healing ulcers. Methods to decrease evaporation, improve wettability and stabilize the tear film, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to improve contact lens tolerability, are provided.

Abstract: The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: A targeted drug delivery complex containing a particle, a targeting moiety electrostatically attached to the particle, and an active pharmaceutical ingredient attached to or dispersed or dissolved within the particle is provided. Also provided are pharmaceutical formulations containing a plurality of the complexes as well as methods for use in targeting an active pharmaceutical ingredient to a selected cell or tissue and production of such formulations.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

Abstract: Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization. The resulting microbubble suspension may be centrifuged to further concentrate the microbubbles. The resulting concentrated LOM suspension preferably has an oxygen content ranging from 50 to 99% (vol). Prior to administration to a patient, the viscosity of the LOM suspension may be reduced to the desired viscosity, preferably similar to the viscosity of the patient's blood. The resulting LOM formulation typically has an oxygen concentration ranging from 65 to 80% (vol). The microbubbles are formed from one or more lipids, preferably one or more phospholipids, most preferably DSPC, and preferably also contain one or more stabilizing agents/excipients, preferably cholesterol.

Abstract: Delivery devices of a degradable or nondegradable biocompatible matrix with one or more encapsulated active pharmaceutical ingredients or one or more particle-bound active pharmaceutical ingredients dispersed in the matrix are provided. Also provided are methods for delivering an active pharmaceutical ingredient to a subject with these delivery devices. Modified vaginal rings are also provided as well as surface coatings for delivery devices which minimize bio-interaction of the coated delivery devices.

Abstract: Formulations containing a carrier and microbubbles encapsulating oxygen gas, and methods for making and using the formulations are described herein. The formulations are manufactured by a process which includes high shear homogenization. The resulting microbubble suspension may be centrifuged to further concentrate the microbubbles. The resulting concentrated LOM suspension preferably has an oxygen content ranging from 50 to 99% (vol). Prior to administration to a patient, the viscosity of the LOM suspension may be reduced to the desired viscosity, preferably similar to the viscosity of the patient's blood. The resulting LOM formulation typically has an oxygen concentration ranging from 65 to 80% (vol). The microbubbles are formed from one or more lipids, preferably one or more phospholipids, most preferably DSPC, and preferably also contain one or more stabilizing agents/excipients, preferably cholesterol.